Sanford Research

Sanford Research, a tax-exempt non-profit organization headquartered in Fargo, North Dakota, operates as a prime recipient of federal biomedical research grants and holds one prime federal service contract, delivering basic and translational research in cancer biology, pediatric disease, neurological disorders, and cellular and molecular biology. The organization is a subsidiary of Sanford Health and maintains a secondary entity, Sanford Research North, within its corporate structure.

Sanford Research's federal footprint centers on the National Institutes of Health, which accounts for 67% of recent awards across 22 distinct NIH institutes and centers. The National Cancer Institute dominates by dollar value, funding 15 awards worth a combined $159 million in potential value—roughly 99% of Sanford's total federal award pipeline. The National Institute of General Medical Sciences follows with 14 awards, the National Institute of Diabetes and Digestive and Kidney Diseases with 4 awards, and the National Human Genome Research Institute with 3 awards. This concentration reflects Sanford's research mission: cancer biology and translational oncology dominate the portfolio, with secondary depth in pediatric disease mechanisms, developmental neuroscience, kidney disease, and metabolic health.

Sanford Research operates overwhelmingly as a prime recipient (87% of 86 tracked awards) rather than as a subcontractor. Recent grant recipients include a $456,500 National Institute of General Medical Sciences Project Grant (awarded March 2026) for research into nuclear envelope regulation and nucleocytoplasmic compartmentalization; a $378,652 National Science Foundation Research Experiences for Undergraduates Site award (February 2024) supporting undergraduate training in cellular and molecular biology across three summers; and a $3.9 million National Cancer Institute Project Grant (May 2025) examining spatiotemporal dynamics of extracellular matrix in ovarian cancer response to platinum therapy. A $3.9 million National Cancer Institute delivery order under the Cancer Study Cohort Recruitment IDIQ (September 2024, ultimate completion September 2026) supports cancer study cohort recruitment and research infrastructure development at Sanford's Sioux Falls facility.

The federal grant portfolio spans basic and translational research with Phase III center awards supporting ongoing capacity building: a Center for Cancer Biology Research operating under NIH COBRE funding (Phase III award April 2023, ultimate completion February 2028) and a Center for Pediatric Research under NIH NIGMS support (Phase III award July 2024, ultimate completion June 2029). Named research areas in recent prime grants include osteosarcoma genetics and p53/Notch-dependent pathways, rhabdomyosarcoma mouse models with Notch inhibition, chimeric antigen receptor-engineered T regulatory cells for Type 1 diabetes control, primary cilia remodeling in neural signaling, head and neck cancer pain mechanisms, renal tubular epithelial transport and myosin dynamics, molybdenum cofactor biology, and cardiac programming following fetal overnutrition in diabetic pregnancy models.

Sanford Research also acts as a subrecipient on grant awards, contributing technical and scientific cores to larger multi-institutional research programs. Sub-award roles include biorepository services and bioinformatics support to the Hugo W. Moser Research Institute at Kennedy Krieger (Batten disease research, awarded December 2025); clinical trial site participation for the Immune Tolerance Network at Benaroya Research Institute (awarded April 2024); and collaborative research on anti-sense oligonucleotide treatment in Batten disease through the University of Michigan (awarded February 2024). Sanford also partners with Vanderbilt University Medical Center on the Integrated, Individualized, and Intelligent Prescribing (I3P) Clinical Trial Network and with the University of North Dakota on the Translational Science Engaging North Dakota (TRANSCEND) Health Research Core.

Activity has grown substantially: four awards in 2022 to twelve in 2024, with six awards recorded in 2025 and one in 2026 (as of the source date). However, recompete risk is concentrated: twelve awards with ultimate completion dates in the next twenty-four months carry a combined potential value of $3.9 million. The Service Contract Inventory dataset captures only five SCI-reportable prime contracts (all above the $150,000 threshold) totaling $1.7 million in invoiced revenue across FY2022–FY2024, with modest FTE growth from 2.3 in FY2022 to 5.6 in FY2024. This SCI activity represents a small sliver of Sanford's total federal research footprint and excludes the substantial grant revenue reflected in the award portfolio. Government-paid rates on SCI-reportable contracts ran with a median of $70.26 per hour, with rates ranging from a 10th percentile of $61.84 per hour to a 90th percentile of $80.33 per hour. Sanford Research does not engage subcontractors on its SCI-reportable contracts; all reported hours are performed by internal staff.